NYSE$TDOC

Teladoc Health Inc · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Teladoc Health's Q3 2024 results reflected a commitment to execution, with initiatives to strengthen the business and unlock future growth.

Teladoc Health reported Q3 2024 revenue of $640.5 million, a 3% decrease year-over-year. Net loss was $33.3 million, or $0.19 per share. The Integrated Care segment saw revenue increase by 2%, while the BetterHelp segment experienced a 10% decrease.

  • Revenue decreased by 3% year-over-year to $640.5 million.
  • Net loss was $33.3 million, or $0.19 per share.
  • Adjusted EBITDA decreased by 6% year-over-year to $83.3 million.
  • Integrated Care segment revenue increased by 2%, while BetterHelp segment revenue decreased by 10%.

Headline financials

Total Revenue

$641M

Previous: $660M-3.0%
EPS

-$0.19

Previous: -$0.35+45.7%
Adjusted EBITDA

$83.3M

No prior period
Operating Cash Flow

$110M

No prior period
Capex

$31.1M

No prior period
Capital Expenditures

-$4.66M

Previous: -$10.1M+53.7%
Free Cash Flow

-$37.9M

Previous: -$67.1M+43.5%
Net Income

-$33.3M

Previous: -$57.1M+41.7%
Operating Income

-$44.4M

Previous: -$64.7M+31.4%
Gross Profit

-$180M

Previous: -$186M+3.3%
Cash & Equivalents

$1.24B

Previous: $1.03B+20.7%
Total Assets

$3.53B

Previous: $4.33B-18.5%
R&D Expense

$72.4M

Previous: $84.3M-14.1%
Stock-Based Comp

$34M

Previous: $53M-35.7%

Revenue & EPS history

Teladoc · Revenue · Quarterly

$641M

Q3 2024-3%vs Q3 2023
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Teladoc · $660M total across 2 segments · Q3 2023

  • Integrated Care
    $374M
  • BetterHelp
    $286M

Forward guidance

Teladoc Health provided financial outlook for the Integrated Care segment for Q4 2024.

Tailwinds

  • Expects Integrated Care revenue growth percentage (year-over-year) of 0% - 2.5%.
  • Expects Integrated Care adjusted EBITDA margin of 12.25% - 13.75%.
  • Anticipates U.S. Integrated Care Members to be 93.5 - 94.5 million.
  • Expects Integrated Care revenue growth percentage for full year 2024 in the low to mid-single digits.
  • Anticipates Integrated Care adjusted EBITDA margin for full year 2024 to be 14.9% - 15.3%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

-1.2%

Avg return

Earnings day

-2.1%

Avg return

5 days after

-1.6%

Avg return

30 days after

49%

21 / 43 earnings

Positive

+23.7%

Q2 2023

Best reaction

-42.0%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.8%+11.9%+27.9%
Q4 2025+15.5%+9.7%+10.5%
Q3 2025+6.2%-3.0%-7.8%
Q1 2025-2.8%-5.7%-3.8%
Q4 2024-13.6%-16.3%-26.4%
Q3 2024+0.9%-0.6%+34.3%
Q2 2024-11.7%-21.9%-26.3%
Q1 2024-5.2%-7.1%-16.4%
Q4 2023-25.6%-31.1%-27.3%
Q3 2023-3.3%-13.5%-5.3%
Q2 2023+23.7%+20.9%-6.1%
Q1 2023+3.4%+2.2%-14.4%
Q4 2022-3.9%-5.4%-12.2%
Q3 2022+6.4%+10.8%+3.2%
Q2 2022-11.4%-8.4%-20.1%
Q1 2022-42.0%-35.7%-38.1%
Q4 2021-5.4%+8.8%+6.8%
Q3 2021+5.6%+7.2%-22.4%
Q2 2021+1.4%-0.9%-5.5%
Q1 2021-10.1%-14.1%-20.7%
Q4 2020-14.2%-12.7%-30.9%
Q3 2020-2.3%-14.6%-11.9%
Q2 2020+11.5%+11.5%-1.9%
Q1 2020-9.1%-3.8%-3.9%
Q4 2019+14.1%+5.1%+38.6%
Q3 2019+7.1%+12.3%+17.1%
Q2 2019+1.9%-6.5%-17.5%
Q1 2019-2.0%+2.9%-1.8%
Q4 2018-4.5%-6.3%-17.5%
Q3 2018+4.6%-8.6%-9.9%
Q2 2018+9.0%+10.3%+29.6%
Q1 2018+5.7%-1.9%+18.4%
Q4 2017+4.0%+8.8%+4.5%
Q3 2017-3.0%-5.4%+8.0%
Q2 2017-7.1%-2.6%+5.5%
Q1 2017+23.3%+26.9%+46.3%
Q4 2016+6.8%-4.8%+13.4%
Q3 2016+6.2%+8.6%+19.4%
Q2 2016-16.1%-9.0%+2.9%
Q1 2016-1.5%
Q4 2015-7.3%
Q3 2015-10.6%
Q2 2015+3.6%
Q1 2015
Q4 2014
Q3 2014
Q2 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro